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Abstracts
Gregory L. Moneta, MD, Section EditorAssociation Between Serum Lipoproteins and Abdominal Aortic
Aneurysm
Golledge J, van Bochxmeer F, Jamrozik K, et al. Am J Cardiol 2010;105:
1480-4.
Conclusion: High-density lipoprotein is the most important lipid in
predicting the risk of development of an abdominal aortic aneurysm (AAA).
Summary: The relationship between dyslipidemia and development of
AAA is unclear. Some studies have reported an association between low-
density lipoprotein (LDL) or high-density lipoprotein (HDL) and AAA;
others have found no association. Previous studies have not used consistent
definitions of dyslipidemia, have not stratified the current use of lipid
modifying medications, and often have not adjusted for other determinants
of AAA. The result has been confusion regarding the role of dyslipidemia in
the development of AAA.
The current study was designed to examine the association of serum
concentration of lipids and AAA in a population screening study. Data were
adjusted for known clinical determinants of AAA and use of lipid-modifying
medications. The study analyzed 3327men aged 65 to 83 years. Analysis was
adjusted for established risk factors of AAA and the presence of prescriptions
of lipid-modifying agents. At the time of fasting lipid measurement, 1043
men (31%) were receiving lipid-modifying therapy; statins in 98% of the
cases. Serum HDL concentrations were lower in patients with AAA. HDL
concentration was independently associated with a decreased risk of an AAA
in men not receiving lipid-modifying therapy (odds ratio, 0.72; 95% confi-
dence interval, 0.56-0.93 per 0.4-mM increase) as well as in the total cohort
(odds ratio, 0.76; 95% confidence interval, 0.63-0.91 per 0.4-mM increase,
adjusted for lipid-modifying therapy). Levels of triglycerides and LDL were
not associated with the presence of AAA.
Comment: The authors have demonstrated a consistent association
between a low serum HDL concentration and the presence of AAA in a
population prone to aortic dilatation. The fact that the association was
present in subgroups not receiving lipid-modifying medications and in men
after adjusting for other risk factors, including lipid-modifying medications,
is evidence modification of HDL levels may be a therapeutic target in the
prevention of AAA.
Atheroembolic Disease—A Frequently Missed Diagnosis: Results of a
12-Year Matched-Pair Autopsy Study
Fries C, Roos M, Gaspert A, et al. Medicine 2010;89:126-32.
Conclusion: Vascular interventions are the most important risk factor
for atheroembolic disease.
Summary: Vascular embolism was first described by Flory in 1944
(Flory CM. Am J Pathol 1944;21:549-58). In cholesterol embolization,
cholesterol crystals are released into the circulation through erosion of an
atherosclerotic plaque. Plaque contents are flushed into the distal arterial
beds and lodged into vessels 150 to 200 m in diameter. The microemboli
trigger an inflammatory reaction that eventually occludes the artery (Keen
RR, et al. J Vasc Surg 1995;21:773-81). Diagnosis of atheroembolic disease
is hampered because atheroembolic disease is associated with multiple
symptoms and has only nonspecific laboratory findings. To better character-
ize this disorder, the authors sought to determine the relative frequency of
autopsy-proven atheroembolic disease during a 12-year period. They sought
to identify risk and precipitating factors and to identify factors that facilitate
diagnosis of atheroembolic disease by identifying laboratory and clinical
features potentially suggesting the disorder.
The authors screened 2066 autopsy reports from 1995 to 2006 for
evidence of atheroembolic disease. For each case of atheroembolic disease, a
control patient without atheroembolic disease was matched for autopsy year,
sex, and age. Records were analyzed for therapeutic and diagnostic interven-
tions in the last 6 months before death as well as laboratory and clinical
parameters during the last hospitalization before death.
They identified 51 patients with atheroembolic disease, and only 6
(12%) had been diagnosed clinically. The most frequently affected organs
were the lower gastrointestinal tract (22%), the spleen (37%), and the kidney
(71%). The frequency of clinically suspected and biopsy-proven atheroem-
bolic disease remained constant over time. Clinical signs increased in patients
with atheroembolic disease were livedo reticularis and blue toes compared
with patients without atheroembolic disease (33% vs 14 %; P  .04). There
was a trend for higher incidence of proteinuria and eosinophilia in the
atheroembolic disease patients. A vascular intervention 6 months before
death was highly associated with atheroembolic disease (55% vs 29%; P 
.01). After multivariable analysis, only a previous vascular intervention was
identified as a significant risk factor for atheroembolic disease.Comment: Atheroembolic disease has been associated with blue toe,
livedo reticularis, renal failure, pancreatitis, muscle pain, gastrointestinalbleeding, hypertension, peptic ulcer, inflammatory bowel disease, prostati-
tis, and hemorrhagic cystitis (Mollenaar W, et al. Am J Gastroenterol
1989;84:1421-2; and Mollenaar W, et al. Arch Intern Med 1996;156:653-
7). The current study confirms the widespread distribution of affected
organs and that atheroembolic disease is missed premorbidly in80% of the
cases. Given the plethora of potential clinical manifestations of atheroem-
bolic disease and that vascular interventions are the major risk factor for
atheroembolic disease, it is likely the complication rate of vascular interven-
tions is higher than suspected based on clinical criteria alone.
Bleeding Complications With Dual Antiplatelet Therapy Among
Patients With Stable Vascular Disease or Risk Factors for Vascular
Disease: Results From the Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Management and Avoidance
(CHARISMA) Trial
Berger PB, Bhatt DL, Fuster V, et al. Circulation 2010;121:2575-83.
Conclusion: There is an increased risk of bleeding with long-term dual
antiplatelet therapy. The increased risk is greatest in the first year. Moderate
bleeding is associated with mortality.
Summary: It is known that dual antiplatelet therapy using clopidogrel
and aspirin is effective in reducing thrombotic events in patients with acute
coronary syndromes and those undergoing placement of bare and drug-
eluting coronary stents. In the original CHARISMA study, on a background
of aspirin therapy, clopidogrel was compared with placebo for amedian of 28
months for its ability to reduce thrombotic events. On this background of
aspirin therapy, clopidogrel did not reduce thrombotic events in the overall
study population (Bhatt DL, et al. N Engl J Med 2006;354:1706-17).
However, in patients with stable vascular disease, clopidogrel added to
aspirin led to a 12% relative decrease in cardiovascular death, myocardial
infarction, or stroke vs those who were treated for risk factors only, where
there was a 20% increase in these events (Bhatt DL, et al. J Am Coll Cardiol
2007;49:1982-88). Because the source of this increased risk in patients with
risk factors only may be bleeding, the authors sought to determine if
bleeding risk was sufficiently high to argue against dual antiplatelet therapy
even in patients with stable vascular disease who appear to benefit from dual
antiplatelet therapy.
The authors analyzed 15,603 patients enrolled in CHARISMA. This
was a double-blind, placebo-controlled, randomized trial comparing clopi-
dogrel (75 mg/d) vs placebo on a background of aspirin therapy (75 to 162
mg/d). Patients in CHARISMA were classified as having stable vascular
disease or multiple risk factors for vascular disease without established
disease. Median follow-up was 28 months. On this background of aspirin
therapy, severe bleeding occurred in 1.7% of the clopidogrel group vs 1.3%
of those treated with aspirin and placebo (P .087), and moderate bleeding
occurred in 2.1% vs 1.3%, respectively (P  .001). The primary risk of
bleeding was during the first year. Patients without severe or moderate
bleeding after 1 year were no more likely than placebo-treated patients to
have subsequent bleeding. Bleeding frequency was similar in patients with
risk factors only and in those with established vascular disease. The relation-
ship between moderate bleeding and all-cause mortality was strong (hazard
ratio [HR], 2.55; 95% confidence interval [CI], 1.71-3.80; P  .0001).
Strong relationships were also between moderate bleeding and myocardial
infarction (HR, 2.92; 95% CI, 1.71-3.8; P  .0001) and stroke (HR, 4.20;
95% CI, 3.05-5.77; P  .0001).
Comment: For the vascular surgeon who frequently treats his or her
patient with dual antiplatelet therapy, the bottom line is that such therapy
will be associated with a risk of moderate or severe bleeding of approximately
4%, and that this risk is greatest in the first year of therapy. In addition,
further analysis of the CHARISMA trial has indicated that in dual antiplate-
let therapy, lower-dose aspirin administered with clopidogrel has a lower risk
of bleeding than higher doses of aspirin (Steinhubl SR et al, Ann InternMed
2009;150:379-86). Overall, dual antiplatelet therapy administered to pa-
tients with established vascular disease lowers the risk of future cardiovascu-
lar events with a small but measurable increased risk of bleeding that, if it
occurs, will adversely affect mortality.
Blunt Traumatic Thoracic Aortic Injuries: Early or Delayed Repair—
Results of an American Association for the Surgery of Trauma Prospec-
tive Study
Demetriades D, Velmahos GC, Scalea TM, et al. J Trauma 2009;66:967-73.
Conclusion: Delayed repair of stable blunt thoracic aortic injury
provides improved survival over emergent repair, irrespective of the presence
of major additional associated injuries.
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